ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
10.03
-0.12 (-1.18%)
At close: Sep 12, 2025, 4:00 PM EDT
10.12
+0.09 (0.90%)
After-hours: Sep 12, 2025, 7:40 PM EDT
ARS Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts that cover ARS Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $31, which forecasts a 209.07% increase in the stock price over the next year. The lowest target is $27 and the highest is $40.
Price Target: $31 (+209.07%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ARS Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth Capital | Roth Capital | Strong Buy Initiates $40 | Strong Buy | Initiates | $40 | +298.80% | Sep 4, 2025 |
| Scotiabank | Scotiabank | Buy Initiates $30 | Buy | Initiates | $30 | +199.10% | Mar 7, 2025 |
| Raymond James | Raymond James | Strong Buy Maintains $26 → $28 | Strong Buy | Maintains | $26 → $28 | +179.16% | Jan 14, 2025 |
| Leerink Partners | Leerink Partners | Buy Maintains $26 → $27 | Buy | Maintains | $26 → $27 | +169.19% | Jan 13, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +199.10% | Oct 8, 2024 |
Financial Forecast
Revenue This Year
85.75M
from 89.15M
Decreased by -3.81%
Revenue Next Year
242.16M
from 85.75M
Increased by 182.40%
EPS This Year
-1.54
from 0.08
EPS Next Year
-0.65
from -1.54
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 92.1M | 258.5M | |||
| Avg | 85.8M | 242.2M | |||
| Low | 77.8M | 222.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.3% | 201.5% | |||
| Avg | -3.8% | 182.4% | |||
| Low | -12.7% | 159.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.46 | -0.18 | |||
| Avg | -1.54 | -0.65 | |||
| Low | -1.58 | -1.25 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.